Opinion Jonathan Kimball of the Association for Accessible Medicines (AAM) in the USA outlines why the signing of the US-Mexico-Canada Agreement (USMCA) in January 2020 may mark a turning point for greater access to generic and biosimilar medicines globally. US trading partners should take note. There is no longer a…
USA The Association for Accessible Medicines’ Chip Davis outlines the ways in which the US Medicare programme needs updating in order to promote generic and biosimilar competition and therefore increase patient access to more affordable medicines. In this election year I hope that the candidates will lay out their solutions…
USA The AAM’s Chip Davis gives an account of his agenda for 2020, how the association is driving policy in a complex healthcare environment of multiple public and private actors and offers insight as to why there is great room for improvement in the uptake of biosimilar drugs. The question,…
Opinion The AAM’s Chip Davis looks back on 35 years of healthcare system savings from generic pharmaceuticals in the US, and the peril the generics industry faces from the Lower Health Care Costs Act. A key provision of our generic pharmaceutical architecture is in jeopardy. The “180-day exclusivity” is the…
Opinion The AAM’s Chip Davis tackles the issue of abandonment within US healthcare and proposes three measures to boost competition, thereby lowering drug prices and reducing abandonment rates. Generic and biosimilar prescription drugs manufactured by member companies of the Association for Accessible Medicines (AAM) play an integral role in the…
Pharma The CSO and COO of BioNovion talk about the company’s recent acquisition by US-based biotech Aduro. BioNovion is a Dutch biopharma specialized in immune oncology antibody discovery. Immunotherapy has become a clinical reality as an effective approach to treat advanced cancer and BioNovion plans to keep leveraging the fruitful collaboration with top-notch research centers…
Pharma Stem cell technology can play a key role in improving the drug discovery process. The CEO of Pluriomics, a biotech company focused on development of fully functional human assay systems for use in drug discovery and development, explains the vision behind the creation of the company as well as the…
Aamal Medical Mr. Shehata, one year after you joined Aamal Medical, Aamal Company went public on the Qatar stock exchange. How did the listing affect your operations at the Medical division? There were many changes implemented, because a number of governance and quality control elements came into the picture. We were faced…
See our Cookie Privacy Policy Here